Genelux (GNLX)

• Market cap: $129M
• 1 day: -4.95%
• 5 days: -0.35%
• 1 month: 1.05%
• 3 months: 9.92%
• 6 months: -30.6%
• Year to date: -36.7%
• 1 year: -4.64%
• 5 years: -53.17%
• 10 years: -53.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Employees: 26